This company listing is no longer active
Flowr Past Earnings Performance
Past criteria checks 0/6
Key information
-49.7%
Earnings growth rate
-20.8%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 44.1% |
Return on equity | -740.2% |
Net Margin | -762.8% |
Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Flowr makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 22 | 12 | -95 | 13 | 1 |
30 Jun 22 | 13 | -99 | 15 | 1 |
31 Mar 22 | 12 | -84 | 14 | 1 |
31 Dec 21 | 12 | -86 | 16 | 2 |
30 Sep 21 | 10 | -118 | 15 | 2 |
30 Jun 21 | 10 | -120 | 16 | 1 |
31 Mar 21 | 10 | -122 | 19 | 1 |
31 Dec 20 | 8 | -126 | 22 | 1 |
30 Sep 20 | 6 | -47 | 26 | 1 |
30 Jun 20 | 4 | -53 | 31 | 1 |
31 Mar 20 | 4 | -36 | 35 | 1 |
31 Dec 19 | 5 | -31 | 33 | 1 |
30 Sep 19 | 8 | -14 | 31 | 0 |
30 Jun 19 | 7 | -4 | 26 | 0 |
31 Mar 19 | 4 | -19 | 20 | 0 |
31 Dec 18 | 3 | -15 | 15 | 0 |
30 Sep 18 | 0 | -11 | 10 | 0 |
30 Jun 18 | 0 | -6 | 7 | 0 |
31 Mar 18 | 0 | -4 | 4 | 0 |
31 Dec 17 | 0 | -2 | 3 | 0 |
Quality Earnings: 2VX is currently unprofitable.
Growing Profit Margin: 2VX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2VX is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.
Accelerating Growth: Unable to compare 2VX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2VX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
Return on Equity
High ROE: 2VX has a negative Return on Equity (-740.24%), as it is currently unprofitable.